We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




MR Imaging Safe for Patients Implanted With Autonomic Heart-Stimulation Device

By MedImaging International staff writers
Posted on 12 May 2022

Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body’s needs for blood and oxygen. The world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure has now received U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR) conditional labeling.

CVRx (Minneapolis, MN, USA) has received US FDA approval for MR conditional labeling for its Barostim System which now includes instructions to allow for safe MRI scans of the head and lower extremities. Barostim is an implantable device that delivers electrical pulses to baroreceptors – natural sensors in the body that tell the nervous system how to regulate heart, kidney and vascular function. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. These effects reduce the heart’s workload and help it pump more efficiently, helping to improve the symptoms for patients with heart failure.

Unlike pacemakers, ICDs, and CRT devices, Barostim does not sense and respond to electrical activity. For this reason, and the presence of a magnetic switch that automatically pauses therapy during an MRI scan, Barostim requires no pre- or post- MRI scan programming (newest models only). All Barostim System patients, including those already receiving Barostim therapy, can safely receive an MRI at 1.5T when conditions of use are met.

"This is a significant milestone for CVRx, and more importantly, for the heart failure patients benefitting from our therapy," said Nadim Yared, President and CEO of CVRx. "These heart failure patients undergo many physical assessments. This approval expands the diagnostic imaging options available to physicians for these patients, should the need arise."

Related Links:
CVRx 

New
Specimen Radiography System
Trident HD
Ultra-Flat DR Detector
meX+1717SCC
Ultrasound Imaging System
P12 Elite
Computed Tomography System
Aquilion ONE / INSIGHT Edition
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to MedImaging.net and get complete access to news and events that shape the world of Radiology.
  • Free digital version edition of Medical Imaging International sent by email on regular basis
  • Free print version of Medical Imaging International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of Medical Imaging International in digital format
  • Free Medical Imaging International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.